TrialBMC cancer2025

Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT.

Maryam Barkhordar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.